A new Twitter thread out today from Yunlong Cao gives further details about the variants BA.2.75 and BQ.1.1.
“Updating information regarding convergent variants BA.2.3.20, BN.1, BA.2.10.4, BN.2.1, BA.4.6.1, BQ.1, BQ.1.1. In short, BA.2.75.2 and BQ.1.1 are the most antibody-evasive convergent variants tested, far exceeding BA.5 and approaching SARS-CoV-1 level. (1/4)”
“BA.2.75.2 is slightly more evasive than BQ.1.1 against plasma from BA.2/BA.5 breakthrough infections. Its due to the enriched NTD-NAbs elicited by BA.2/BA.5 infections, which BQ.1.1 can’t escape. Note that these variants are approaching SARS-CoV-1 level escaping capability. (2/4)“
“As expected, BQ.1.1 escapes Evusheld and bebtelovimab, making all clinically available antibody drugs ineffective. BQ.1.1 and BA.2.75.2 both displayed sufficient hACE2 binding capability. (3/4)”
“We should be able to update information on BU.1, BR.2, BM.1.1.1, CA.1, and XBB within two weeks. I agree with @CorneliusRoemer that XBB will be the most immune-evasive convergent variant for now, since it should be able to escape the majority of both NTD/RBD NAbs. (4/4)”
Do we have any idea what protection bivalent [vaccines] will afford against these?
“I don’t think the current WT/BA.1 or WT/BA.5 bivalent vaccines would be very effective against those convergent variants, based on the released mouse vaccination data.”
Yunlong Cao has already featured in two other posts on Coronaheadsup.com about BA.2.75.2 and other variants of interest. You can find the posts here and here.
Cornelius Roemer: “BQ.1.1 is showing quite some growth, especially in England where the first sample was submitted 9 days ago and now there are already 28 sequences. I hope there is some sort of biased sampling going on. Otherwise this doesn’t look good.”
BQ.1.1 is showing quite some growth, especially in England where the first sample was submitted 9 days ago and now there are already 28 sequences. I hope there is some sort of biased sampling going on. Otherwise this doesn't look good.@PeacockFlu@kallmemeg@theosandersonpic.twitter.com/cteUne84Cv
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
